Recent therapeutic targets in diabetic nephropathy. Issue 11 (10th August 2021)

• Record Type: Journal Article
• Authors: Mohsen, Marwa; Elberry, Ahmed A.; Mohamed Rabea, Alaa; Abdelrahim, Mohamed E. A.; Hussein, Raghda R. S.
• Is Part Of: International journal of clinical practice. Volume 75:Issue 11(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-10
• Subjects: albuminuria -- CKD -- diabetic nephropathy -- DPP‐4 inhibitors -- T2D; Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.14650
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Background: The prevalence of diabetes mellitus has been increased dramatically which in turn leads to complications including cardiovascular diseases, diabetic kidney disease, and substantially end‐stage renal disease. Methods: We reviewed articles discussing the pathophysiology of diabetic nephropathy with new agents that may be useful in the management of the disease. We used PubMed, Scopus, Google Scholar and the Open‐access searching engines. Results: The recent recommendations primarily depend on glycaemic and blood pressure control and the use of standard renin‐angiotensin system blockade. Currently, the use of agents with nephroprotective effects beyond the hyperglycaemic lowering effect has been evidenced clinically. Conclusions: In his review, the pathophysiology, clinical manifestations, and lines of treatment of diabetic nephropathy are discussed. In addition, a focus on the clinical role and nephroprotective effects of the emerging therapeutic class, dipeptidyl peptidase IV (DPP‐4) inhibitors, is addressed in detail.